| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Glecaprevir/Pibrentasvir |
| Brand | Maviret® |
| Indication | For the treatment of chronic hepatitis C virus (HCV) infection in adults – pangenotypic GT1-6. |
| Assessment Process | |
| Rapid review commissioned | 11/07/2017 |
| Rapid review completed | 17/08/2017 |
| Rapid review outcome | Full pharmacoeconomic assessment not recommended. |